SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)
RIGL 35.20-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (30)1/29/2002 2:29:46 PM
From: keokalani'nui  Read Replies (1) of 566
 
Oh, and while I am at it, I meant to add a couple nuggets added at the very end of the presentation.

1. PFE has accepted its allergy/asthma target
2. JnJ recently extended the cell cycle pathway partnership another 2 years (commenced in 1999)
3. Novartis b- and t- cell regulation program in autoimmune and transplant rejection is progressing
4. Company says about its proprietary tnf program that it has found targets in the TNF pathway that are specific to cell types; and there is tosco
5. The HepC program is based on a novel approach, intervening at the ribozyme expression site, and 'works well' in early animal models by preventing replication

Only in its 4th year of operation. 30 targets validated with human physiology. Every collaboration extended or expanded. Most talk was on the mast cell program.

Would like to hear opposing views because i may be looking to own some more of this soon notwithstanding crappy market, overhang from secondary

Wilder
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News